Treatment options for patients with advanced biliary tract cancer are limited. Dysregulation of the immune system plays an important role in the pathogenesis of biliary tract cancer (BTC). This study aimed to investigate whether tremelimumab, an anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitor, could be combined safely with microwave ablation to enhance the effect of anti-CTLA4 treatment in patients with advanced BTC. Patients were enrolled to receive monthly tremelimumab (10 mg/kg, intravenously) for six doses, followed by infusions every 3 months until off-treatment criteria were met. Thirty-six days after the first tremelimumab dose, patients underwent subtotal microwave ablation. Interval imaging studies were performed every 8 weeks. Adverse events (AEs) were noted and managed. Tumor and peripheral blood samples were collected to perform immune monitoring and whole-exome sequencing (WES). Twenty patients with refractory BTC were enrolled (median age, 56.5 years). No dose-limiting toxicities were encountered. The common treatment-related AEs included lymphopenia, diarrhea, and elevated transaminases. Among 16 patients evaluable for efficacy analysis, 2 (12.5%) patients achieved a confirmed partial response (lasting for 8.0 and 18.1 months, respectively) and 5 patients (31.3%) achieved stable disease. Median progression free survival (PFS) and overall survival (OS) were 3.4 months (95% confidence interval [CI], 2.5-5.2) and 6.0 months (95% CI, 3.8-8.8), respectively. Peripheral blood immune cell subset profiling showed increased circulating activated human leukocyte antigen, DR isotype ([HLA-DR] positive) CD8+ T cells. T-cell receptor (TCR)β screening showed tremelimumab expanded TCR repertoire, but not reaching statistical significance (P = 0.057). Conclusion: Tremelimumab in combination with tumor ablation is a potential treatment strategy for patients with advanced BTC. Increased circulating activated CD8+ T cells and TCR repertoire expansion induced by tremelimumab may contribute to treatment benefit. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
Treatment options for patients with advanced biliary tract cancer are limited. Dysregulation of the immune system plays an important role in the pathogenesis of biliary tract cancer (BTC). This study aimed to investigate whether tremelimumab, an anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitor, could be combined safely with microwave ablation to enhance the effect of anti-CTLA4 treatment in patients with advanced BTC. Patients were enrolled to receive monthly tremelimumab (10 mg/kg, intravenously) for six doses, followed by infusions every 3 months until off-treatment criteria were met. Thirty-six days after the first tremelimumab dose, patients underwent subtotal microwave ablation. Interval imaging studies were performed every 8 weeks. Adverse events (AEs) were noted and managed. Tumor and peripheral blood samples were collected to perform immune monitoring and whole-exome sequencing (WES). Twenty patients with refractory BTC were enrolled (median age, 56.5 years). No dose-limiting toxicities were encountered. The common treatment-related AEs included lymphopenia, diarrhea, and elevated transaminases. Among 16 patients evaluable for efficacy analysis, 2 (12.5%) patients achieved a confirmed partial response (lasting for 8.0 and 18.1 months, respectively) and 5 patients (31.3%) achieved stable disease. Median progression free survival (PFS) and overall survival (OS) were 3.4 months (95% confidence interval [CI], 2.5-5.2) and 6.0 months (95% CI, 3.8-8.8), respectively. Peripheral blood immune cell subset profiling showed increased circulating activated human leukocyte antigen, DR isotype ([HLA-DR] positive) CD8+ T cells. T-cell receptor (TCR)β screening showed tremelimumab expanded TCR repertoire, but not reaching statistical significance (P = 0.057). Conclusion:Tremelimumab in combination with tumor ablation is a potential treatment strategy for patients with advanced BTC. Increased circulating activated CD8+ T cells and TCR repertoire expansion induced by tremelimumab may contribute to treatment benefit. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Samuel J Wang; Andrew Lemieux; Jayashree Kalpathy-Cramer; Celine B Ord; Gary V Walker; C David Fuller; Jong-Sung Kim; Charles R Thomas Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Lidia Robert; Jennifer Tsoi; Xiaoyan Wang; Ryan Emerson; Blanca Homet; Thinle Chodon; Stephen Mok; Rong Rong Huang; Alistair J Cochran; Begoña Comin-Anduix; Richard C Koya; Thomas G Graeber; Harlan Robins; Antoni Ribas Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531
Authors: Edward Cha; Mark Klinger; Yafei Hou; Craig Cummings; Antoni Ribas; Malek Faham; Lawrence Fong Journal: Sci Transl Med Date: 2014-05-28 Impact factor: 17.956
Authors: Bruno Sangro; Carlos Gomez-Martin; Manuel de la Mata; Mercedes Iñarrairaegui; Elena Garralda; Pilar Barrera; Jose Ignacio Riezu-Boj; Esther Larrea; Carlos Alfaro; Pablo Sarobe; Juan José Lasarte; Jose L Pérez-Gracia; Ignacio Melero; Jesús Prieto Journal: J Hepatol Date: 2013-03-04 Impact factor: 25.083
Authors: Thomas Walter; Anne M Horgan; Mairead McNamara; Liz McKeever; Trisha Min; David Hedley; Stefano Serra; Monika K Krzyzanowska; Eric Chen; Helen Mackay; Ronald Feld; Malcolm Moore; Jennifer J Knox Journal: Eur J Cancer Date: 2012-09-01 Impact factor: 9.162
Authors: Changqing Xie; Austin G Duffy; Gagandeep Brar; Suzanne Fioravanti; Donna Mabry-Hrones; Melissa Walker; Cecilia Monge Bonilla; Bradford J Wood; Deborah E Citrin; Elizabeth M Gil Ramirez; Freddy E Escorcia; Bernadette Redd; Jonathan M Hernandez; Jeremy L Davis; Billel Gasmi; David Kleiner; Seth M Steinberg; Jennifer C Jones; Tim F Greten Journal: Clin Cancer Res Date: 2020-01-29 Impact factor: 12.531
Authors: Cecilia Monge; Erica C Pehrsson; Changqing Xie; Austin G Duffy; Donna Mabry; Bradford J Wood; David E Kleiner; Seth M Steinberg; William D Figg; Bernadette Redd; Anuradha Budhu; Sophie Wang; Mayank Tandon; Lichun Ma; Xin Wei Wang; Tim F Greten Journal: Oncologist Date: 2022-03-11
Authors: María Gutiérrez-Larrañaga; Elena González-López; Adriel Roa-Bautista; Pedro M Rodrigues; Álvaro Díaz-González; Jesus M Banales; Marcos López-Hoyos; Alvaro Santos-Laso; Javier Crespo Journal: Liver Cancer Date: 2021-09-21 Impact factor: 11.740